Functional imaging with MRI contrast agents is an emerging experimental approach that can combine the specificity of cellular neural recording techniques with noninvasive whole-brain coverage. A variety of contrast agents sensitive to aspects of brain activity have recently been introduced. These include new probes for calcium and other metal ions that offer high sensitivity and membrane permeability, as well as imaging agents for high resolution pH and metabolic mapping in living animals. Genetically-encoded MRI contrast agents have also been described. Several of the new probes have been validated in the brain; in vivo use of other agents remains a challenge. This review outlines advantages and disadvantages of specific molecular imaging approaches and discusses current or potential applications in neurobiology.
Introduction
As neuroscientists become increasingly brave in their efforts to study the functioning of neural systems in vivo, there is a growing need for measurement methods that can record comprehensive information about the functioning of living brains. Magnetic resonance imaging (MRI) is a special tool in this regard, because of its relatively high spatial resolution (∼ 10 μm in high magnetic field scanners) and capacity to scan entire organisms noninvasively. Functional MRI (fMRI) with contrast dependent on cerebral hemo-dynamics provides an indirect readout of neural activity [1] [2] [3] . Although hemodynamic fMRI has had transformative impact in cognitive science, the techniques lack the specificity and temporal precision of electrophysiology and optical imaging, and have not been widely used in basic neurobiology experiments.
Another way to exploit the unique advantages of MRI for neuroscience is to perform the imaging in conjunction with molecular probes (contrast agents) sensitive to aspects of neuronal physiology [4] . This approach is roughly analogous to performing optical neuroimaging with fluorescent dyes, but is currently far less well-developed. Most MRI contrast agents are paramagnetic chemicals that increase parameters called the T 1 and T 2 relaxation rates of water, as observed in tissue and solution; T 1 or T 2 relaxation enhancements produce image brightening or darkening, respectively. Additional classes of contrast agents work by a chemical exchangebased mechanism called CEST [5] , or involve imaging nonstandard nuclei like 19 F and 13 C. The characteristics and physical mechanisms of different types of contrast agent are discussed at length in a number of book chapters and reviews [6] [7] [8] [9] [10] [11] , and are summarized in Figure 1 . In general, for any agent to be used in functional imaging, either its ability to influence MRI contrast or its spatial distribution must be sensitized to neural activity in some way.
The past few years have seen significant advances in the design of new MRI contrast-based sensors and the introduction of protein contrast agents for brain imaging. These are nascent technologies-few of the efforts have progressed beyond an in vitro or proof-of-concept stage, but in several cases experiments using the new agents in animals can now be performed. The remainder of this review describes contrast agents suitable for functional imaging based on metal ions, pH, metabolic activity, and gene and protein expression. Prospects for future development and application of molecular fMRI methods are discussed.
Indicators for Ca 2+ and other metal ions
Calcium ions are an important target for neuroimaging agents because neuronal calcium fluxes are dramatic and directly related to synaptic activity. Recent two-photon fluorescence imaging studies have demonstrated the power of calcium measurements to characterize neuronal population behavior in exposed regions of the brain [12, 13] . MRI indicators for calcium can facilitate calcium imaging of deep tissue structures. Several relaxation-based contrast agents for calcium-dependent MRI have been introduced. An increasingly widespread approach was introduced by Koretsky and colleagues, who showed that Mn 2+ functions as a paramagnetic Ca 2+ mimetic and accumulates activity-dependently in neurons [14, 15] . Because of its slow uptake and release kinetics (on the order of hours and days, respectively [16]), Mn 2+ has proved useful as an "activity label" analogous to 2-deoxyglucose or c-Fos. The technique was recently used for 100 μm isotropic resolution T 1 -weighted mapping of auditory cortex in mice [17] , and for a functional study of the antennal lobes of developing moths [18] .
A contrast agent sensor designed for real-time calcium imaging was developed by Li et al. [19] . The agent was formed by attaching the calcium chelator 1,2-bis-(O-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid (BAPTA) to two copies of the highly paramagnetic gadolinium complex Gd 3+ -1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (Gd-DOTA); the agent undergoes a change in T 1 relaxivity (a measure of efficacy) near 1 μM Ca 2+ . Delivery of the sensor to neurons in sufficient quantity for functional imaging in vivo has not yet been reported. Partly in response to this situation, Atanasijevic et al. [20] have now described a new family of calcium sensors derived from extremely potent superparamagnetic iron oxide (SPIO) nanoparticle contrast agents. SPIOs were conjugated to "tunable" recombinant proteins that drove reversible particle aggregation around a midpoint of 0.8 μM Ca 2+ and produced over 100% T 2 -weighted MRI signal changes in vitro. A key advantage of the these agents is that because of their high relaxivity, they may be used at concentrations (∼ 1 nM) that are both easier to deliver and less disruptive to cellular calcium dynamics than Gd 3+ -based sensors (effective at 10−100 μM). A disadvantage of the SPIO calcium sensors is that they respond relatively slowly to calcium changes [21] . As with the Gd 3+ -based calcium sensors, fMRI with SPIO sensors could be possible once effective intracellular delivery strategies are harnessed; SPIO uptake by brain cells in vivo has been demonstrated [22, 23] .
Ions of transition metals such as zinc and copper are also influenced by neural activity, and alterations of transition metal homeostasis have been associated with a number of neuropathologies. Gadolinium-based sensors for zinc [24] and copper [25] , similar to the Li et al. [19] 
pH indicators
The extracellular medium becomes slightly acidified during neural activity [27] . Although these changes (in the range from pH 7.2−7.4) are not restricted to individual neurons, they could be monitored by pH-sensitive probes and used for functional fMRI. Both relaxation and CEST-based MRI contrast agents work by mechanisms that involve water or proton exchange ( Figure 1A-C) , which are inherently pH dependent and therefore easily compatible with pH sensing. In fact, a diverse set of pH indicators for MRI has been described (reviewed in [28] ), though none of the indicators has yet been demonstrated to detect changes in neuronal activity. In one of relatively few in vivo studies, Garcia-Martin et al. [29] used a phosphonated Gd 3+ -based contrast agent to measure intravascular acidification in rat gliomas. Differences of the order of one pH unit could be distinguished, and absolute pH values were obtained using a calibration procedure [30] . The contrast agent used in this study experiences changes in T 1 relaxivity over the broad range from pH 6−8 [31] ; the sensor could in principle be applied for functional brain imaging, following intracranial injection or blood-brain barrier disruption, but MRI signal changes would be expected to be less than one percent under realistic pH fluctuations (< 0.2 units) and agent concentrations (∼ 100 μM). Synthesis of novel sensors optimized for sensitivity in the pH 7.2−7.4 range may therefore be critical to developing this approach for fMRI. An alternative is the use of intrinsic protein amide proton contrast for CEST-related pH imaging in the brain [32] . Initial studies applied this method to detect focal ischemia in rats, involving pH changes on the order of 0.5 units.
Probes for metabolic activity
Changes in metabolic activity are closely coupled to neural signaling, and MRI contrast agents sensitive to cellular respiration may be used for functional imaging. Given evidence that metabolic processes including the consumption of oxygen are locally regulated on a much faster timescale than changes in hemodynamics [33] , direct monitoring of these variables could provide more precise information about brain function than hemodynamic fMRI techniques can. The best known oxygen sensitive contrast agent is the endogenous iron containing protein hemoglobin, which underlies blood oxygen level dependent (BOLD) contrast [34] . Hemoglobin can also be used as an exogenous sensor in tissue [35] , but it does not seem to provide enough sensitivity to detect rapid deoxygenation events ("initial dips") associated with changes in neural activity. Cerebral metabolite uptake has traditionally been measured using radioactive glucose analogs, in conjunction with positron emission tomography (PET) or postmortem autoradiography. Golman et al. [36] have now introduced a sophisticated technique for performing similar experiments by MRI. The technique involves following the kinetics of a 13 C-labeled metabolite, pyruvate, by 13 C MRI ( Figure 1D ). Normally, 13 C MRI is too insensitive to detect pyruvate at physiologically relevant concentrations, but here the authors used a method called dynamic nuclear polarization to boost the MRI signal from 13 C 1 -pyruvate using a specialized device [37] . Kinetics of pyruvate uptake and turnover to lactate and alanine were followed in the muscles and abdominal organs of rats and pigs. Whether this or related approaches can be useful for functional brain imaging is unclear at present. Principal difficulties involve the relatively rapid decay of MRI signal from the tracer (time constant 15−20 s in vivo), the fact that other metabolites (e.g. glucose) have much shorter decay times, and the need in fMRI applications for periodic or continuous supply [38] of polarized agents to the brain.
Genetically-controlled contrast agents
The discovery of green fluorescent protein (GFP) and the development of genetically-encoded fluorescent indicators like cameleons [39] and synaptophluorins [40] are continuing to revolutionize the modern practice of neuroscience. Unlike fluorescent proteins, genetically encodable contrast agents (most of them paramagnetic metalloproteins) are plentiful in nature, but it is only in the past few years that any of these have been exploited as ectopically expressed markers for imaging. The iron storage protein ferritin (Ft) encloses a core of ferrihydrite with partially superparmagnetic properties, making Ft a close natural analog of SPIO contrast agents [41] . In a 2005 paper, Genove et al. [42] demonstrated that viral-mediated overexpression of Ft in mouse brain led to clear changes in T 2 -weighted images (Figure 2A ). Iron loading and relaxivity changes induced by Ft can be boosted by co-expressing transferrin receptor, another participant in endogenous iron metabolism [43] . A recent report has now shown that Ft subunits expressed in transgenic mice can be detected in multiple tissue types and in utero without pathological side-effects [44] , suggesting that Ft may find broad utility as a marker protein in MRI. This study showed that Ft expression even in relatively sparse endothelial cells led to detectable contrast changes ( Figure 2B ). Another protein contrast agent was cleverly designed by Gilad et al. [45] , who boosted the concentration of exchangeable amine protons in transfected cells using an artificial lysine rich protein (LRP). Using the CEST MRI method (see Figure 1C) , cells expressing the LRP could be distinguished from controls both in test tubes and in xenografted tumors ( Figure 2C ). Unlike Ft, which requires iron loading to induce contrast, LRP is a contrast agent as soon as it is translated; this may permit LRP expression changes to be detected on a shorter timescale than changes in Ft levels. On the other hand, MRI signal changes reported by Gilad et al. [45] were relatively subtle and required long imaging times to resolve (> 30 min.), and it is not yet known whether LRP expression-mediated contrast may be generalized easily to other contexts.
How could genetically encoded contrast agents be used for functional brain imaging? Although this has not been reported, a technically straightforward approach would be to express a protein contrast agent under control of a promoter known to be regulated by neural activity, like those of immediate early genes (IEGs) fos and arc. Because IEG protein induction generally persists for hours [46] , a method like this would not be useful for functional imaging on the timescale of conventional fMRI or neurophysiology techniques, but it could be used in fairly simple (and potentially longitudinal) mapping studies in animals, somewhat like Mn 2+ labeling technique discussed above. A more exciting direction from the perspective of systems neuroscience would be the engineering of MRI sensors for neural activity using protein contrast agents as building blocks. Key advantages of genetically encoded sensors over synthetic sensors include the possibility that they might be genetically targeted to specific cell types, the relative ease of delivering genes vs. imaging agents, and the fact that protein contrast agents may be cheaper to use and easier to modify than many synthetic contrast agents.
Genetic mechanisms can be used to direct MRI contrast due to exogenous agents; "semigenetic" approaches to functional imaging might offer better sensitivity than protein contrast agent expression, particularly if high relaxivity agents or enzymatic amplification strategies are incorporated. Initial examples included detection of lacZ marker expression in developing frog embryos using a gadolinium-chelating β-galactosidase substrate [47] , and monitoring of a transferrin receptor reporter gene in mice using transferrin-conjugated SPIOs [48] . Semigenetic contrast mechanisms based on a variety of marker proteins and receptors have now been reported (reviewed in [49] [50] [51] ), and design of contrast agents targeting RNA transcripts has also been described [52, 53] . Measurement of biological processes in the nervous system
has not yet been convincingly demonstrated, however.
Conclusions
A number MRI contrast agents with potential utility for functional imaging have been discussed. Table 1 summarizes advantages and disadvantages of many of the approaches. Although some of the contrast agents have been applied in animals, only Mn 2+ dependent labeling has so far been used for functional imaging of neural activity. For basic neuroscience studies, none of the new techniques is currently a surrogate for hemodynamic fMRI or invasive neural recording methods. Major progress has been achieved recently, however, with the development of new MRI probes for sensitive detection of brain-related physiological variables and the introduction of protein and genetically-controlled contrast agents. Several of these agents have been used to make measurements in vivo; applications to functional neuroimaging appear feasible in some cases, perhaps within the next five years. In addition to the persistent challenges of obtaining sensitivity and specificity for neural events, a hurdle in developing molecular fMRI techniques further will be the need to distinguish molecular signatures of activity from hemodynamic responses. Validation experiments in reduced preparations and in animals with suppressed BOLD responses may be valuable. Future work in this area will certainly focus on extending applications of the existing contrast agents in live animals, the development of more genetically-controlled probes, and the creation of MRI sensors for previously unexplored aspects of neural signaling, such as membrane potential and neurotransmitter release.
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BOLD
Blood Oxygenation Level Dependent Signal in MRI is proportional to the concentration of directly detected nuclei in the specimen (usually protons in water molecules), the degree to which these nuclei are polarized by the scanner's magnetic field, manipulations due to MRI acquisition schemes called pulse sequences, and the relaxation rates (T 1 and T 2 ) that determine how quickly nuclei in the specimen return to equilibrium after being manipulated by the pulse sequence. (A) Paramagnetic atoms promote T 1 relaxation-based contrast in conventional MRI by interacting with water molecules (left). Gadolinium atoms (green) are effective at this because of their high electron spin (S = 7/2); Mn 2+ (S = 5/2) and a variety of other metal ions may also be used. These atoms are often incorporated into chelates (Gd 3+ -dielthylenetriaminepentaacetic acid shown) to improve solubility and reduce toxicity. Relaxation occurs when water molecules (cyan) sample magnetic field perturbations (yellow) created by the paramagnetic atom, either through direct coordination (dotted gray line), or through space. Sensors may be constructed by making aspects of this interaction dependent on an environmental variable or molecular target. T 1 -weighted imaging (right) may be performed using a variety of pulse sequences. Following one or more pulses (vertical gray bars), image data are acquired in the Fourier domain (black trace). Repetition of the pulse sequence causes progressive attenuation due to saturation of the signal, toward a steady state value that determines image intensity (top right). Addition of a T 1 contrast agent relieves this effect (bottom right) and leads to image brightening in areas where the contrast agent is concentrated. (B) Although most paramagnetic contrast agents induce both T 1 and T 2 relaxation, superparamagnetic nanoparticles including SPIOs have the highest T 2 relaxivity, and relatively low T 1 relaxivity. SPIOs typically contain a core of iron oxide 3−10 nm diameter (green), surrounded by a biocompatible organic coating with a total diameter of 10−100 nm (gray). Particles induce magnetic perturbations (yellow) that induce relaxation of water molecules diffusing in proximity (blue arrows). The particle size and shape of its field perturbation influence its relaxivity [54] -this relationship is the basis of sensors formed by making SPIO aggregation dependent on presence of a target molecule [55] . T 2 relaxation occurs during the time between each application of the pulse sequence and acquisition of the signal (black traces, right). Addition of a T 2 contrast agent causes reduction of the MRI signal (bottom right) and leads to image darkening in areas where the contrast agent is concentrated. (C) Chemical exchange saturation transfer (CEST) contrast can be produced using agents with exchangeable protons that have MRI resonance frequencies (chemical shifts)
well resolved from the frequency of water molecules [5] . The example shown is the indole nitrogen proton (indigo) of 5-hydroxytryptophan. The spectrum of chemical shifts in a solution of this agent is schematized by the gray trace at the bottom left, where resonances of the CEST agent protons and water protons are indicated by indigo and cyan arrowheads, respectively. CEST contrast is produced by modifying a typical imaging pulse sequence to include a continuous saturation pulse or pulse train (red box, bottom right) matched to the frequency of the CEST protons. The saturation pulse directly decreases MRI signal due to the CEST protons (which are usually too dilute to image), but indirectly reduces signal from water protons (cyan arrowhead) because they are in exchange with the CEST proton pool. This effect leads to local darkening of MRI signal in areas where CEST agents are concentrated; contrast may be turned on and off by changing the power or frequency associated with the saturation pulse. Sensors may be based on modulation of the exchange rate or resonance frequency of labile protons on a CEST agent. (D) Contrast agents incorporating 13 C, 19 F, or a variety of other nuclei may be imaged directly using modified MRI hardware. Images of 13 C agent distribution may be formed, analogous to standard proton images, but typically with much lower resolution and signal-to-noise ratio. Spectroscopic imaging techniques measure the distribution of species with different chemical shifts at each position in space (red trace). In experiments of Golman et al. [36] , carbon resonances of 13 C 1 -labeled pyruvate (green) and its reduction product 13 C 1 -lactate (gray) could be distinguished using this approach (right). Relative amounts of the two species were indicative of local metabolic rate. Images like the one shown (left) were obtained only with the use of 13 C-labeled agents that had been hyperpolarized to boost MRI signal, prior to imaging [37] . Figure 1C ) in mouse brains containing xenografted 9L rat glioma cells expressing LRP (left, cyan arrowhead) or GFP (right, red arrowhead). CEST signal (0.56 mm in-plane resolution at 11.7 T) is expressed as percent intensity difference with respect to baseline in the brain (color scale), overlaid on a corresponding anatomical image (gray). LRP expressing tumors showed 8.2 ± 3.2% intensity difference, vs. 3.5 ± 3.3% for controls. Apparent CEST contrast outside the brain is due to magnetic field inhomogeneities, which dramatically influence results from this technique. Scale bar = 2 mm. Adapted from ref.
[45] with permission. Contrast independent of prosthetic groups; may be "switched" on and off.
Long image acquisition times usually required with CEST mechanism.
Gd 3+ -binding substrate (EGadMe) for β-galactosidase [47] Injected frog embryos expressing β-gal showed ∼ 50% signal changes.
Low levels of β-gal detected. Widespread use of β-gal as a marker.
Exogenous agent must be delivered. Relaxivity change is irreversible.
Transferrin (Tf)-conjugated SPIOs [48] Tumors expressing transferrin receptor distinguished from controls.
SPIO agent detectable at low levels. Receptor catalyzes agent uptake.
Exogenous agent required. Contrast slow to build up and reverse.
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